Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint inhibitors, such as Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb), over the past decade has significantly altered the treatment paradigm. In the first-line setting, Keytruda is the current SOC, while Erbitux (Eli Lilly [United States] / Merck KGaA [EU5]) is prescribed for PD-L1-negative or immunotherapy-ineligible patients. In the second-line setting, Keytruda is approved as monotherapy, regardless of PD-1 expression. However, there is a strong need for effective therapies that prolong overall survival in this patient population. In addition, there is an unmet need for patients with non-nasopharyngeal SCCHN who have progressed after treatment with immune checkpoint inhibitors because there are no established therapies for this patient population.
Questions answered
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions for recurrent or metastatic non-nasopharyngeal SCCHN?
- How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities that drug developers could leverage in the treatment?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile?
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 65 U.S. and 35 European medical oncologists
Key drugs covered: Erbitux, Keytruda, Opdivo
Key analyses
Importance of clinical and nonclinical product attributes to physicians
Assessment of current drug performance against treatment drivers and goals
Physician perceptions of unmet needs in the indication and related indications
Remaining drug development opportunities
